# Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC

> **NCT07693959** · PHASE3 · RECRUITING · sponsor: **Zhiquan Hu** · enrollment: 170 (estimated)

## Conditions studied

- MIBC

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Toripalimab
- **DRUG:** Disitamab Vedotin (RC48)
- **PROCEDURE:** Radical Cystectomy

## Key facts

- **NCT ID:** NCT07693959
- **Lead sponsor:** Zhiquan Hu
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07693959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07693959, "Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07693959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*